Business Wire

UBITUS

Share
Ubitus K.K. to Showcase at VivaTech 2024, Highlighting Innovations in AIGC and Cloud Gaming

Ubitus K.K. (hereinafter Ubitus), a leading cloud gaming technology provider, is thrilled to announce its participation in Viva Technology 2024, Europe’s biggest startup and tech event, taking place from May 22nd to May 25th at Paris Expo Porte de Versailles. Visitors can explore Ubitus' innovative solutions at Booth D38 in the TTA Pavilion, Hall 1, where you can express your creativity through Ubitus’ AI solutions.

Innovative Demonstrations at the Ubitus Booth

Ubitus is excited to showcase its AI technologies that increase creativity and productivity for everyone, including the debut of Ubi-chan in French and UbiArt, its visual art AI generative tool. Ubi-chan, Ubitus' AI V-tuber, will engage with attendees, providing an interactive experience that highlights the capabilities of AI in entertainment. Additionally, Ubitus will unveil UbiArt at the event, featuring unique “local style models” like the Taiwan Night Market, demonstrating the versatile applications of its technology in creating culturally rich digital art.

Keynote Speeches by CEO Wesley Kuo

Cloud vs Console: The Future of Gaming Platforms
Highlighting Ubitus' involvement, CEO Wesley Kuo will take the stage as an official speaker at VivaTech. Wesley Kuo is scheduled to present on "Cloud vs Console: The Future of Gaming Platforms" on May 23, from 9:45 AM to 10:30 AM on Stage 2. His speech session with Michael Fan, partner of Galaxy Interactive, and Joe Tidy, Cyber Correspondent of BBC News will address crucial topics in the gaming industry, discussing the transformative potential of cloud technology over traditional console platforms, impacts on market dynamics, the benefits of subscription-based models, and the implications for data privacy and game diversity. For more details on the session, please visit: https://vivatechnology.com/sessions/4a3a33b1-f2f0-ee11-aaf0-000d3a2b945f.

Introduction to Ubitus' AI Solutions
In addition, Wesley Kuo will deliver a second presentation on the main stage in the TTA Pavilion(Booth D38) at 2 PM on the same day, focusing on Ubitus' AI-driven initiatives.

Ubitus' participation in VivaTech 2024 showcases its commitment to innovation and its role in shaping the future of digital entertainment and AI applications. By introducing AI solutions like Ubi-chan, who will engage visitors in French, and UbiArt, which captures the essence of local cultures, showcasing the vibrant Taiwanese food culture, Ubitus is set to make a significant impact at this global tech event.

Join us at Viva Technology 2024 to experience the future of technology with Ubitus' innovative solutions. We look forward to welcoming you to our booth and sharing our vision for a connected world. For more information, please visit Ubitus K.K. website.

About Ubitus K.K.

Ubitus K.K. is a technology company that specializes in cloud solutions, GPU virtualization technology, and cloud streaming platform. Our focus is on delivering exceptional cloud and artificial intelligence services.

Leveraging the power of GPUs, Ubitus has developed multiple AI solutions, including UbiGPT (Taiwan LLM), Ubi Anchor (AI anchor), Ubi-chan (AI character), and UbiArt (image generation software). Ubitus is committed to delivering tailor-made solutions designed to meet the diverse requirements of customers in various industries. Our goal is to seamlessly incorporate a range of AI applications into distinctive situations, ensuring a customized approach for each use case.

Ubitus’ cloud gaming solution enables users to enjoy AAA gaming experiences across devices with just an internet connection. Through our comprehensive Game Development Kit (GDK), we offer patented technology for rapid deployment, catering towards international clients that are interested in cloud gaming, including console gaming platforms, telecom operators, and game developers.

For Metaverse solutions, Ubitus possesses extensive global cloud deployment experience via GameCloud® technology offerings. Ubitus is able to stream interactive media content for platform operators and digital content developers on multi-devices, which offers users an immersive experience that accelerates metaverse popularization.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240515534843/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Welcomes Increased Equity Investment From L’Oréal8.12.2025 07:05:00 CET | Press release

L’Oréal to acquire an additional 10% stake in Galderma recognizing its scientific leadership in dermatology and long-term growth potential Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers). Following the transaction, which is subject to customary approvals, L’Oréal’s total shareholding in Galderma will rise to 20%, building on its initial investment made in August 2024. The transaction is expected to close in Q1 2026. In connection with this increased investment, Galderma will consider nominating two non-independent board candidates from L’Oréal, replacing the board members representing the consortium led by EQT, at the 2026 Annual General Meeting. Additio

Ant International Wins Champion of NeurIPS Competition of Fairness in AI Face Detection8.12.2025 04:37:00 CET | Press release

The Challenge: Deepfakes undermine both the accuracy and fairness of AI face detection due to variations in human features.The Technology: Ant International’s AI model uses a novel ‘Mixture of Experts’-based Adversarial Debiasing approach to achieve superior fairness and accuracy across diverse demographics.The Impact: This advancement strengthens payment security, offering robust protection against deepfake fraud and enhancing eKYC compliance globally. Ant International, a leading global digital payment, digitisation, and financial technology provider, has won first place at the NeurIPS Competition of Fairness in AI Face Detection. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207210856/en/ Ant International’s solution takes top spot at the NeurIPS Competition of Fairness in AI Face Detection, emerging first among over 2,100 submissions from 162 teams globally. AI Fairness enhances Financial Security Studies by the Nati

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye